Navigation Links
ReVision's Fenretinide (RT-101) Reduced Incidence of Choroidal Neovascularization by More Than 50 Percent in Patients With Geographic Atrophy in a Phase 2b Trial
Date:9/1/2010

f 164 patients (9.2 percent) receiving fenretinide at either dose developed CNV. While the results were statistically significant (p=0.039), this was the result of exploratory and ad hoc analyses.

Preclinical studies show that fenretinide reduces the expression of vascular endothelial growth factor (VEGF) isoforms. These proteins are known to cause aberrant growth of leaky vessels within the retina and have been implicated in severe vision loss in patients with CNV. Fenretinide was also found to upregulate the expression of complement factor H, a potent inhibitor of the inflammatory pathway. Dysfunction or deficits in complement factor H are known to significantly increase risk for development of CNV. This preclinical data suggests that the anti-angiogenic and anti-inflammatory properties of fenretinide may underlie the reduced incidence of CNV observed in the clinical trial.

The accumulation of retinol (vitamin A)-derived toxins in the eye is believed to be a significant risk factor for the development of GA. The ability of fenretinide to reduce the delivery of retinol to the eye, and therefore reduce accumulation of these toxins, is thought to mitigate this risk. Analysis of GA lesion growth by color fundus photography showed a trend for slowing of lesion growth in patients receiving fenretinide. This trend was particularly evident in patients in the 300 mg dose group who had substantial reductions in serum retinol and its carrier protein, retinol binding protein (RBP). Data from the 300 mg dose group demonstrated a reduction in median lesion growth when RBP and retinol levels were reduced by more than 50 percent. This finding supports the proof of concept that reduction of circulating RBP and retinol reduces lesion growth in patients with GA.

Full analysis of all lesion size measurements is ongoing. The complete data will be presented later this year at the annual meeting of the American Academy of Ophthalmology.

About ReVision The
'/>"/>

SOURCE ReVision Therapeutics Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Soliris(R) Reduced Measures of Thrombosis and Inflammation, and Decreased Indicators of Pulmonary Hypertension, in Studies of Patients with PNH
2. Pressure BioSciences, Inc. Reports Record Revenue, Significantly Reduced Operating Loss for the Fourth Quarter of 2008
3. Multiple Types of Heart Attacks Reduced by Prasugrel in TRITON-TIMI 38 Trial
4. Cord Blood America Says Debt Reduced $4.194 Million in 2009
5. Reorganizational Healing Provides Access to Greater Quality of Life, Reduced Stress
6. China Yongxin Pharmaceuticals Projects Higher Net Income and EPS on Reduced Revenue for Full-Year 2009
7. The toxicity of antimicrobial silver in products can be reduced
8. Orexigen(R) Therapeutics Announces That Contrave(R) Reduced Depression Scores and Body Weight in Overweight and Obese Patients With Major Depression
9. Teriflunomide Significantly Reduced Annualized Relapse Rate and was Well Tolerated in MS Patients
10. Retrospective Analysis of Phase 3 Data Suggest Wyeths Investigational Compound Bazedoxifene/Conjugated Estrogens Comparable to Placebo on Incidence of Abnormal Mammograms
11. Half of Surveyed Physicians Expect to Replace Between 6 Percent and 15 Percent of Their Sustiva Prescriptions with Isentress
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/19/2014)... 2014 Biotech companies make announcements ... drug systems and advanced Laboratory Instrumentation. Companies in focus ... BDX ), Thermo Fisher Scientific Inc. (NYSE: ... RGDO ), Sangamo Biosciences Inc. (NASDAQ: ... Pressure BioSciences, Inc. (OTCQB: PBIO) ("PBI" or the "Company") ...
(Date:9/19/2014)... -- Pfenex Inc. (NYSE MKT: PFNX), a clinical-stage biotechnology ... to manufacture proteins including biosimilar therapeutics, today announced that ... Annual NewsMakers in the Biotech Industry conference in ... chief executive officer of Pfenex, will provide an overview ... Friday, September 26, 2014 at 10:00 a.m. EDT/7:00 a.m. ...
(Date:9/19/2014)... September 19, 2014 Barnhardt Manufacturing ... Label for its Organic Cotton . The USDA ... of renewable biobased ingredients meets or exceeds levels set ... composed in whole or in significant part of agricultural, ... allow our Organic cotton to be immediately identified as ...
(Date:9/19/2014)... Dublin ... announced the addition of the  "Micro Market Monitor ... offering.       (Logo: http://photos.prnewswire.com/prnh/20130307/600769) , , ... fastest-growing segments in the chromatography market. The market ... expected to reach $2.0 billion by 2019, at ...
Breaking Biology Technology:Medical Instrumentation Automation Advances for Biological Sample Preparation - Company Expects Q4 Revenue Impact from Newest Instrument Systems 2Medical Instrumentation Automation Advances for Biological Sample Preparation - Company Expects Q4 Revenue Impact from Newest Instrument Systems 3Medical Instrumentation Automation Advances for Biological Sample Preparation - Company Expects Q4 Revenue Impact from Newest Instrument Systems 4Medical Instrumentation Automation Advances for Biological Sample Preparation - Company Expects Q4 Revenue Impact from Newest Instrument Systems 5Medical Instrumentation Automation Advances for Biological Sample Preparation - Company Expects Q4 Revenue Impact from Newest Instrument Systems 6Medical Instrumentation Automation Advances for Biological Sample Preparation - Company Expects Q4 Revenue Impact from Newest Instrument Systems 7Pfenex to Present at Upcoming Industry Conference on September 26 2Barnhardt Manufacturing Company Earns USDA Certified Biobased Product Certification and Label for Organic Cotton 2Micro Market Monitor : Global Pre-packed Chromatography Columns 2
... NEOG ) has expanded its line of ... quickest test available for tetracycline residues,in milk. The ... treat,bovine mastitis, and includes tetracycline, chlortetracycline, and,oxytetracycline., ... the company,s widely used BetaStar(R) test for the ...
... Philadelphia Area -, PHILADELPHIA, Feb. 13 ... announced today the appointment of Chris Tihansky as,its ... Paris-based Mauna,Kea Technologies and develops and markets Cellvizio(R), ... care by eliminating the,need for unnecessary biopsies and ...
... Advance Nanotech, Inc.,(OTC Bulletin Board: AVNA), a leader in ... special meeting of shareholders held at,Company headquarters in New ... increase the authorized number of shares of Capital stock ... shares,present at the meeting were voted in favor of ...
Cached Biology Technology:Neogen Launches Quickest Test Available for Tetracyclines in Milk 2Chris Tihansky Appointed President of In Vivo Cellular Imaging Leader Cellvizio Inc. 2Advance Nanotech Announces Shareholder Proxy Vote Results 2Advance Nanotech Announces Shareholder Proxy Vote Results 3
(Date:9/19/2014)... professor will study the unique bioelectric signaling system of ... people,s health. The OU researcher is working to ... produce the signals used to map the world around ... rate of 500-600 discharges a second throughout their lives. ... are extreme, but necessary for survival. , "There is ...
(Date:9/19/2014)... legume plants regulate their symbiotic relationship with soil ... through the plant structure from leaves into the ... in the roots. This collaborative study was conducted ... Biology, the Graduate University for Advanced Studies (SOKENDAI), ... in Japan. , Legumes, an important plant ...
(Date:9/18/2014)... ANTONIO, September 18, 2014 New research into the ... causes a severe hemorrhagic disease in humans similar to ... essential for CCHFV infection. This discovery has the potential ... the pathogen. , The research, reported in ... Pathogens and conducted by scientists at the Texas ...
Breaking Biology News(10 mins):For legume plants, a new route from shoot to root 2Research milestone in CCHF virus could help identify new treatments 2
... engineers have proposed a new environmentally friendly process for ... - potentially available from agricultural and forest waste, providing ... transportation sector." , The new approach modifies conventional methods ... from a "carbon-free" energy source, such as solar or ...
... study in PLoS Medicine has shown that children who ... children, and who have antigens (protein fragments from the ... infectious virus in their blood. Margaret Conner and colleagues ... obtained from hospitalized children with gastroenteritis and compared them ...
... transcendent entity answer prayer? , The answer, according to ... March journal Research on Social Work Practice, is “yes.?David ... the College of Human Services at Arizona State University, ... the effects of intercessory prayer ?or prayer that is ...
Cached Biology News:New biofuels process promises to meet all US transportation needs 2New biofuels process promises to meet all US transportation needs 3New biofuels process promises to meet all US transportation needs 4Does God answer prayer? ASU research says 'yes' 2
2.0 GHz Compaq Computer with 512 MB RAM, 32 MB AGP Graphics Card, 40 GB Hard Drive, 1 Serial Port & Open PCI Slot, Windows 2000 OS, MS Office, CD Read/Writer and 18 Flat Panel Monitor...
Blot Paper 7 x 8.5cm semi-dry western blots (order number RB-400)...
... Normal;heading 1;heading ... types and experimental ... for standard transfection ... transduction systems. ViraPower ...
... System with Gateway™ Technology is designed ... the polyhedrin promoter. The expression cassette ... (bacmid DNA) by site-specific transposition (Tn7) ... recombinant bacmid DNA is then used ...
Biology Products: